We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders.

Our clinical-stage pipeline includes VTX3232, a Phase 2 ready CNS-penetrant inhibitor of the NLRP3 inflammasome, VTX2735, a Phase 2 ready peripheral inhibitor of the NLRP3 inflammasome, VTX002, a Phase 3 ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX958, a Phase 2 allosteric TYK2 inhibitor for the treatment of Crohn’s disease.